Can-Fite BioPharma Ltd. Deferred Tax Assets, Operating Loss Carryforwards
Can-Fite BioPharma Ltd. (CANF) had Deferred Tax Assets, Operating Loss Carryforwards of $32.81 million as of 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $32.81M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $27.00M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $25.61M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $25.14M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $32.81M 20-F · filed 2026-03-26 | |
| 2024-12-31 | $27.00M 20-F · filed 2026-03-26 | |
| 2023-12-31 | $25.61M 20-F · filed 2025-04-14 | |
| 2022-12-31 | $25.14M 20-F · filed 2024-03-28 | |
| 2021-12-31 | $26.35M 20-F · filed 2023-03-30 | $37.88M 20-F · filed 2022-03-24 |
| 2020-12-31 | $32.31M 20-F · filed 2022-03-24 | |
| 2019-12-31 | $27.29M 20-F · filed 2021-03-25 | |
| 2018-12-31 | $22.93M 6-K · filed 2020-06-01 |